| 000 | 01423 a2200361 4500 | ||
|---|---|---|---|
| 005 | 20250517023446.0 | ||
| 264 | 0 | _c20150526 | |
| 008 | 201505s 0 0 eng d | ||
| 022 | _a1432-0584 | ||
| 024 | 7 |
_a10.1007/s00277-015-2316-0 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPfirrmann, Markus | |
| 245 | 0 | 0 |
_aPrognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death. _h[electronic resource] |
| 260 |
_bAnnals of hematology _cApr 2015 |
||
| 300 |
_aS209-18 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 | _aCause of Death |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xdiagnosis |
| 650 | 0 | 4 | _aPractice Guidelines as Topic |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aProtein-Tyrosine Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 |
_aRisk Assessment _xmethods |
| 700 | 1 | _aLauseker, Michael | |
| 700 | 1 | _aHoffmann, Verena S | |
| 700 | 1 | _aHasford, Joerg | |
| 773 | 0 |
_tAnnals of hematology _gvol. 94 Suppl 2 _gp. S209-18 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00277-015-2316-0 _zAvailable from publisher's website |
| 999 |
_c24747071 _d24747071 |
||